CD8A and neoplasm: In the tumour site, abundant ROS induced degradation of the hydrogel that locally released gemcitabine (GEM) and anti-PD-L1 blocking antibodies (aPDL-1), triggering marked infiltration of CD4+ and CD8+ T lymphocytes and even systemic immune responses that inhibited tumour growth and recurrence (Fig. 9b–f).